CSF1R and neoplasm: Pre- and on-treatment biopsies across multiple tumor types in patients being treated with cabiralizumab and nivolumab showed an increase of CD8 lymphocytes mirrored by a reduction of CD163+ CSF1R+ Mф (NCT02526017) [45].